SB-408124
SIGMA/S2694 - ≥98% (HPLC), solid
Synonym: N-
CAS Number: 288150-92-5
Empirical Formula (Hill Notation): C19H18F2N4O
Molecular Weight: 356.37
MDL Number: MFCD06411575
Linear Formula: C19H18F2N4O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | off-white |
| form | solid |
| InChI | 1S/C19H18F2N4O/c1-11-8-17 |
| InChI key | JTARFZSNUAGHRB-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100  |
| SMILES string | CN(C)c1ccc(NC(=O)Nc2cc(C) |
| solubility | DMSO: >10 mg/mL |
| storage temp. | 2-8°C |
| Application: | SB-408124 was used to block orexin A-mediated cardiovascular effects in rats. It was used to study block the increase of endogenous glucose production mediated by bicuculline in rats. |
| Biochem/physiol Actions: | SB 408124 is an OX1 orexin receptor antagonist. |
| Biochem/physiol Actions: | SB-408124 blocks the orexin type 1 receptor that stimulates the production of stress hormone in hypothalamus. It blocks orexin A-induced increase in arterial pressure and elevation of heart rate in rats. SB-408124 modulates phrenic nerve activity that is important in respiration. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Legal Information: | Sold for research purposes under agreement from GlaxoSmithKline |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |